Brief: Lee's Pharmaceutical Updates On Trial Of Adapalene-Clindamycin Combination Gel In China
22/06/2020 10:12
June 22 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* LEE'S PHARMACEUTICAL- UNIT SUCCESSFULLY COMPLETED ITS
PIVOTAL
PHASE III TRIAL OF ADAPALENE-CLINDAMYCIN COMBINATION GEL IN
CHINA
* LEE'S PHARMACEUTICAL- NEW DRUG APPLICATION SUBMISSION AND
MARKETING APPROVAL EXPECTED IN SECOND HALF OF 2020 AND IN 2021,
RESPECTIVELY
Source text for Eikon: ID:nHKSbxps5Q
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA